collaboration

Invitae will provide genetic testing for 109 genes associated with the conditions, while BioMarin will provide financial support for the program.

The firms noted that QuantuMDx’s Capture-XT technology will enable downstream drug-susceptibility analysis, PCR, NGS, and, with this collaboration, nanopore detection.

Amgen's latest deal with a pharma company will see its clonoSeq assay used for minimal residual disease testing in a clinical trial for venetoclax.

Spartan's test is for the rapid, near-patient determination of a cardiac patient's genotype for aid in determining appropriate antiplatelet treatment.

Germany's Life & Brain Genomics hopes to streamline sample management and genetic array input for its multi-omics analysis services.

Members, spouses, and adult dependents from 13 locals will have access to Color's genomic services, including physician-ordered genetic tests.

Working with MPEG-G booster GenomSys, SysMeta IT will integrate the new data compression specification into its Tangerine Medical platform to support clinicians.

The companies aim to develop technologies for interpreting cancer genome data, with a focus on linking genetic profiles with treatment responses.

Asuragen will use its Amplidex PCR tech to develop companion diagnostics for Wave's investigational allele-selective therapeutic programs for Huntington's.

Tokyo-based Eisai develops drugs primarily for the neurology and oncology markets, including treatments for Parkinson's disease and breast cancer.